Company / Capital Expenditures
ARS Pharmaceuticals, Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$339.0K
FY2025
5-year range
$55.0K / $563.0K
FY2021-FY2025
Trend
-39.8%
vs FY2024
Sector context
#146 of 194
Health Care
What the data says
ARS Pharmaceuticals, Inc.'s capital expenditures of $339,000 is lower than 75% of companies in the Health Care sector (FY2025). Improved from $175,000 to $339,000 over the past 2 years.
Based on SEC 10-K filings.
$339,000 in FY2025 with a 5-year CAGR of -18.0%.
Improved from $175,000 to $339,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +83.3%
- 5-Year CAGR
- -18.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 194This company $339.0K Sector average $117.5M
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -18.0%, indicating a declining trend.
- In FY2025, capital expenditures decreased 39.8% year-over-year.
- Ranks #146 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $339.0K | -39.8% |
| FY2024 | $563.0K | +221.7% |
| FY2023 | $175.0K | +218.2% |
| FY2022 | $55.0K | +0.0% |
| FY2021 | $55.0K | -94.0% |
| FY2020 | $917.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026